HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class (Ascending) | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Q5127 | Pegflilgrastim-fpgk | Stimufend | 0.5mg | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | No | 2022 | March 17, 2023 | In Use | ||
Q5130 | Pegfilgrastim-pbbk | Fylnetra | 0.5mg | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | No | 2022 | March 17, 2023 | In Use | ||
J9032 | Belinostat | Beleodaq | 10 mg | Chemotherapy | Enzyme Inhibitor | HDAC | No | 2014 | Jan. 1, 2016 | In Use | ||
NA | Panobinostat | Farydak | 10 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2015 | In Use | |||
NA | Panobinostat | Farydak | 15 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2015 | In Use | |||
NA | Panobinostat | Farydak | 20 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2015 | In Use | |||
C9265 | Romidepsin | Istodax | 1 mg | Chemotherapy | Enzyme Inhibitor | HDAC | No | 2009 | July 1, 2010 | Dec. 31, 2010 | No Longer Used | |
J9315 | Romidepsin | Istodax | 1 mg | Chemotherapy | Enzyme Inhibitor | HDAC | No | 2009 | Jan. 1, 2011 | Sept. 27, 2021 | No Longer Used | |
NA | Vorinostat | Erivedge | 100 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2006 | In Use | |||
C9065 | Romidepsin | Romidepsin | 1mg | Chemotherapy | Enzyme Inhibetor | HDAC | No | 2020 | Jan. 1, 2021 | Sept. 27, 2021 | No Longer Used | |
J9318 | Romidepsin, non-lyophilized | Romidepsin | 0.1mg | Chemotherapy | Enzyme Inhibitor | HDAC | No | 2020 | Sept. 27, 2021 | In Use | ||
J9319 | Romidepsin, lyophilized | Istodax | 0.1mg | Chemotherapy | Enzyme Inhibitor | HDAC | No | 2010 | Sept. 27, 2021 | In Use | ||
J9354 | Ado-Trastuzumab Emtansine | Kadcyla | 1mg | Immunotherapy | Drug Antibody Conjugate | HER2 | No | 2013 | Jan. 1, 2014 | In Use | ||
C9131 | Ado-Trastuzumab Emtansine | Kadcyla | 1mg | Immunotherapy | Drug Antibody Conjugate | HER2 | No | 2013 | July 1, 2013 | Dec. 31, 2013 | No Longer Used | |
C9292 | Pertuzumab | Perjeta | 10 mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2012 | Oct. 1, 2012 | Dec. 31, 2013 | No Longer Used | |
J9306 | Pertuzumab | Perjeta | 1 mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2012 | Jan. 1, 2014 | In Use | ||
J9355 | Trastuzumab | Herceptin | 10 mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 1998 | Jan. 1, 2000 | In Use | ||
Q5113 | Trastuzumab-pkrb | Herzuma | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2018 | July 1, 2019 | In Use | ||
Q5114 | Trastuzumab-dkst | Ogivri | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2017 | July 1, 2019 | In Use | ||
J9356 | Trastuzumab and Hyaluronidase-oysk | Herceptin hylecta | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2019 | July 1, 2019 | In Use | ||
Q5117 | Trastuzumab-anns | Kanjinti | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2019 | Oct. 1, 2019 | In Use | ||
J9316 | Pertuzumab, Trastuzumab, Hyaluronidase-zzxf | Phesgo | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2020 | Jan. 1, 2021 | In Use | ||
J9353 | Margetuximab-cmkb | Margenza | 5mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2021 | July 23, 2021 | In Use | ||
NA | Tucatinib | Tukysa | 50mg,150mg | Chemotherapy | Tyrosine Kinase Inhibitor | HER2 | Yes | 2020 | In Use | |||
Q5116 | Trastuzumab-qyyp | Trazimera | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2020 | Oct. 1, 2019 | In Use |
Found 716 results in 1 millisecond — Export these results
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.